Research programme: phosphodiesterase 7 inhibitors - Omeros

Drug Profile

Research programme: phosphodiesterase 7 inhibitors - Omeros

Alternative Names: OMS 527; PDE7 inhibitors - Omeros; Type 7 cyclic nucleotide phosphodiesterase inhibitors - Omeros

Latest Information Update: 16 May 2016

Price : $50

At a glance

  • Originator Asubio Pharma; Omeros Corporation
  • Developer National Institute on Drug Abuse; Omeros Corporation; The Parkinsons Institute and Clinical Center
  • Class
  • Mechanism of Action Type 7 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Drug abuse; Impulse control disorders; Movement disorders

Most Recent Events

  • 10 May 2016 Omeros has patent protection for phosphodiesterase-7 inhibitors in the US
  • 19 Mar 2013 Research programme is still in preclinical trials for Drug abuse in US
  • 22 Feb 2011 Omeros extends its licence to phosphodiesterase 7 inhibitors from Asubio (Daiichi Sankyo) to include Impulse control disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top